MeiraGTx Holdings plc (MGTX) reported third-quarter 2026 revenue of $4.8 million and a net loss attributable to ordinary shareholders of $51.3 million, or $0.53 per basic and diluted ordinary share.
The company said its marketing authorization application for bota-vec in X-linked retinitis pigmentosa is expected to be submitted to the European Medicines Agency in December 2026, followed by a U.S. biologics license application in the first quarter of 2027.
- Cash, cash equivalents and restricted cash were $186.8 million at September 30, 2026, compared with $17.1 million a year earlier.
- Service revenue was $1.6 million and related-party service revenue was $3.2 million during the quarter.
- The Phase 2 AQUAx2 study of AAV2-hAQP1 for radiation-induced xerostomia remains on track for a 12-month data readout in mid-2027.
- MeiraGTx expects to initiate a single- and multiple-ascending-dose study of its lead riboswitch small molecule in December 2026.
- The company appointed John Knighton as executive vice president of global manufacturing and supply chain and Alan M. Sebulsky to its board during the quarter.
$MGTX Insider Trading Activity
$MGTX insiders have traded $MGTX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MGTX stock by insiders over the last 6 months:
- ALEXANDRIA FORBES (PRESIDENT & CEO) has made 0 purchases and 2 sales selling 124,000 shares for an estimated $1,427,860.
- RICHARD GIROUX (CFO & COO) has made 0 purchases and 2 sales selling 112,000 shares for an estimated $1,257,760.
- STUART NAYLOR (CHIEF SCI OFCR, OPHTHALMOLOGY) has made 0 purchases and 3 sales selling 55,318 shares for an estimated $703,761.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MGTX Hedge Fund Activity
We have seen 113 institutional investors add shares of $MGTX stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROSIGHT MANAGEMENT, LP removed 2,539,971 shares (-96.6%) from their portfolio in Q2 2026, for an estimated $34,315,008
- RUBRIC CAPITAL MANAGEMENT LP added 2,100,000 shares (+30.0%) to their portfolio in Q2 2026, for an estimated $28,371,000
- BLACKROCK, INC. added 1,589,030 shares (+50.2%) to their portfolio in Q2 2026, for an estimated $21,467,795
- OPALEYE MANAGEMENT INC. added 1,426,741 shares (+67.2%) to their portfolio in Q2 2026, for an estimated $19,275,270
- WOODLINE PARTNERS LP added 1,199,812 shares (+399.5%) to their portfolio in Q2 2026, for an estimated $16,209,460
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,001,433 shares (+7324.2%) to their portfolio in Q2 2026, for an estimated $13,529,359
- HEIGHTS CAPITAL MANAGEMENT, INC added 850,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,483,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
